

EVALUATION OF BONE MARROW BIOPSY IN THE DETECTION OF MICROMETASTASES IN BREAST CANCER

Thesis

Submitted for Partial Fulfillment of **Doctorate Degree** in
Clinical Pathology and Oncologic Laboratory Medicine

By

Hala Mohamed El-Negily Abd El-Al
M.B.,B.Ch;M.Sc

Supervised by

Prof. Dr. Amira Mokhtar Khorshed

Professor of Clinical Pathology
National Cancer Institute
Cairo University

Dr. Mohamed Abd El-Rahman Ahmed

Assistant Professor of Clinical Pathology
Military Academy of Medicine
Armed Forces Hospital - Alexandria

Dr. Amr El-Sayed Zaher

Fellow of Clinical Pathology
National Cancer Institute
Cairo University

Clinical Pathology Department
National Cancer Institute
Cairo University
2009

EVALUATION OF BONE MARROW BIOPSY IN THE DETECTION OF MICROMETASTASES IN BREAST CANCER

Summary:

Key words: Breast cancer, BM micro-metastases, BM disseminated tumor cells, BM Minimal residual disease.

The present study included 51 female patients divided in to two groups: patient and control groups. The patient group composed of 36 primary, apparently non metastatic [stage I, II or III] breast cancer patients, and none of them had received chemotherapy before, while the control group composed of 15 female cases with NHL were included in this study as control group. BMA and Biopsy were performed, CA15.3 levels were measured in both serum and BMA plasma for both patients and control group. BMB sections were stained with both conventional H&E stain as well as immunohistochemically using a panel of monoclonal antibodies directed against Cytokeratin, Mammaglobin and CA15.3 antigens. Cases were considered positive for BM micro-metastases when at least 2 monoclonal antibodies are positive. Morphological examination detected only 4 of 36 [11.1%] cases positive for micro-metastases. IHC staining detected 9 of 36 [25%] cases positive for CK, 15 of 36 [41.7%] cases positive for CA15.3 and 11 of 36 [30.6%] cases positive for MAM McAbs. Total interpretation of IHC staining detected 13 of 36 [36.1%] positive for micro-metastatic breast cancer cells. No significant correlation between BM micro-metastases and regional lymph node involvement. BMB was superior to BMA in the detection of BM-DTCs. The sensitivity of BMB for DTC detection was enhanced by multi-IHC staining of BMB sections. Although there was correlation between serum and BMA plasma CA15.3 levels in both patients and controls group, there was no correlation between neither serum nor BMA plasma CA15.3 levels and the totally interpreted BM micro-metastases with breast cancer cells.

عنوان الرسالة

تقييم عينات النخاع العظمي في اكتشاف الانتشار المبكر لسرطان الثدي

ملخص الرسالة

الكلمات الدالة: سرطان الثدي ، انتشار مبكر في النخاع

تم اجراء الدراسة على ٣٦ مريضة سرطان الثدي في المراحل الاولى قبل اخذ أى علاج و تضمنت الدراسة ١٥ مريضة بسرطان الغدد الليمفاوية كمجموعة التحكيم. تم سحب و أخذ عينات من النخاع العظمي و سحب عينات في كل من الدم و بلازما النخاع العظمي CA15.3 من الدم لعمل صورة دم كاملة و قياس دلالات الاورام ومقارنة النتائج في كل منهما و مقارنتهما مع نتائج مجموعة التحكيم. قطعت عينات النخاع العظمي و تمت كما تم صبغ شرائح النخاع بطريقة الصبغات المناعية للأنسجة و [H&E] صبغتها بالصبغات العادية للأنسجة و Cytokeratin- Mammaglobin and CA15.3 :ذلك باستخدام مجموعة من الأجسام المضادة وهي ذلك للكشف عن خلايا الثدي السرطانية منتشرة في النخاع.

ACKNOWLEDGEMENT

All prays to **ALLAH** for guiding my efforts towards success in this work.

I would like to express my deepest appreciation and gratitude to **Professor Dr. Amira Mokhtar Khorshid**, Professor of Clinical Pathology, National Cancer Institute, Cairo University, for her continuous, extremely valuable scientific aid, moral support and giving me the privilege to work under her honest supervision.

A special attribute and cordial thanks with deep appreciation and gratitude to **Dr. Mohamed Abd El-rhman Ahmed**, Assistant Professor of Clinical Pathology, Military Academy of Medicine, Armed Forces Hospital, Alexandria, for his great help, continuous encouragement and excellent suggestion during this work.

I am also deeply grateful to **Dr. Naglaa Kholousy**, Assistant Professor, of Clinical Pathology, National Research Center, for her great effort, valuable help and much assistance she made in the statistical work of thesis.

I shall always remain greatly indebted and much obliged to **Dr. Amr El-saied Zaher**, Fellow of Clinical Pathology, National Cancer Institute, Cairo University, for his excellent guidance, unfailing support and actual cooperation since start of this work.

CONTENTS

Acknowledgment	I
Contents	II
List of Tables	IV
List of Figures	VI
List of Abbreviations	VIII
Aim of work	1
Review of Literature:	
Chapter I: Breast Cancer	
I-Factors contribute to breast cancer development.....	2
II-Classifications of breast cancer.....	4
III- Metastatic Breast Cancer.....	10
Chapter II: Methods for detection of BM disseminated tumor cells	
●Antibody based techniques.....	22
-Immunocytochemistry.....	22
-Fluorescence microscopy.....	25
- Flowcytometry.....	25
- EPISPOT.....	25
- ELISPOT.....	25
●Nucleic acid based techniques.....	26
- Polymerase chain reaction.....	26
- Reverse transcriptase polymerase chain reaction.....	27
- Qauntitative reverse transcriptase polymerase chain reaction	27
-Flourescence in situ hybridization.....	28
Chapter III: Markers used for the detection of BM-DTCs in breast cancer patients	
I-Markers with low breast [cancer] specificity.....	29
1-Cytokeratins.....	29
2- HER-2/neu[ERBB2].....	32
3-Epithelial membrane antigen [EMA].....	32
4- Mucins [MUC1].....	32
5-Epithelial growth factor receptor [EGFR].....	32
II-Markers with high breast [cancer] specificity.....	33
1-Mammaglobin.....	33
2-Prolactin-inducible protein [PIP]	35

3-SERPINB5.....	35
●Serologic markers used in breast cancer.....	36
1-CA15-3 and CA27-29.....	37
2- CEA.....	40
3-HER-2/ECD.....	42
Chapter IV: Bone Marrow pathology in metastatic diseases	
●Bone marrow aspiration & trephine biopsy	44
1-Indications for bone marrow trephine biopsy in malignant diseases.....	45
2-The role of bone marrow biopsy in the detection of metastatic diseases.....	48
3-Unexplained hematologic abnormalities associated with BM metastases.....	49
4-Bone marrow findings in metastatic diseases	51
5-Bone marrow findings in breast carcinoma.....	54
6-Difficulties in the diagnosis of metastatic tumor cells in BM.	55
7-Problems and pitfalls in BM trephine biopsy interpretations.....	55
Material &Methods	57
Results	70
Discussion	97
Conclusion and recommendations	107
References	108
Arabic summary	١

LIST OF TABELS

No	Table Title	Page
1.1	TNM classification of breast cancer	9
1.2	Correlation of UICC (1987) and TNM classifications of tumors	9
2.1	Preparations done for any formalin fixed, paraffin embedded marrow section before any staining	61
3.1	A comparison between morphological detection rates of "Cytological" versus "Histological" examinations, for marrow micrometastatic breast cancer cells among patient group as well as controls group	67
3.2	A comparison between "Histological" versus "Immunocytochemical" detection rates, for marrow micrometastatic breast cancer cells among patients group as well as controls group	77
3.3	Significance of immunohistochemical detection of micrometastatic breast cancer cells in the histologically suspicious and negative marrow sections of breast cancer patients	78
3.4	Comparison between the detection rates (sensitivities) of CA15-3, Mammaglobin and Cytokeratin (AE1/AE3) McAbs, used to highlight metastatic breast cancer cells of 36 breast cancer patients	79
3.5	The possible methods of IHC total interpretation for the 36 BC patients, using a panel of 3 McAbs, were depending upon the considerations of positivity and negativity which in turn were depending on the number of positive and negative McAbs found among the used panel	80
3.6	Correlations between serum and BMA plasma levels of CA15-3 in breast cancer patients group and control group, correlations in CA15-3 serum levels between breast cancer patients group and controls group as well as correlations in CA15-3 BMA plasma levels between breast cancer patients group and controls group	81

3.7	Correlations between CA15-3 serum and BMA plasma levels on one side and each of IHC-stained marrow sections using CA15.3 McAb and totally interpreted IHC-stained marrow sections and histologically examined marrow sections on the other side for the 36 breast cancer patients	82
3.8	Correlation between the distant bone marrow involvement by micrometastatic breast cancer cells (detected by total interpretation of IHC-stained marrow sections) and regional (Axillary) lymph node involvement (detected by routine histo-pathological examination) in the studied 36 breast cancer patients	83
3.9	Clinical, pathological and laboratory data of breast cancer patients group	84
3.10	Clinical and laboratory data of controls group	85

LIST OF FIGURES

1- BMB shows fibrotic areas with increased angiogenesis and morphologically query para vascular micrometastatic deposits, H&E, 20X.....	86
2- Higher magnifications of figure -1, 40X.....	86
3- BMB showing single micrometastatic sheet of 4 tumor cells near capillary blood vessel H&E, 40X.....	87
4- Higher magnification of figure -3, 100X.....	87
5- BMB showing single micrometastatic sheet of 3-4 tumor cells H&E, 100X.....	88
6- BMB showing morphologically query micrometastatic sheet H&E, 20X...	88
7- BMB showing morphologically query micrometastatic sheet, H&E, 40X..	89
8- Higher magnification of figure -7, 100X.....	89
9- BMB showing morphologically query micrometastatic sheet, H&E, 100X..	90
10- BMB showing morphologically query micrometastatic sheet of 4 cells showing indian file arrangement, H&E, 100X.....	90
11- Hypocellular BM aspiration showing metastatic sheet in breast cancer patient, 20X	91
12- Higher magnification of figure -11, 100X.....	91
13- Another case with hypocellular BM aspiration showing rare metastatic sheet in breast cancer patient, 20X.....	92
14- Higher magnification of figure -3.....	92

15- IHC- stained BMB showing few scattered DTCs arranged individually or in doubles and show positivity for CA15-3 McAb, 20X.....	93
16- IHC-stained BMB showing 4 DTCs that are positive for CA15-3 McAb, 40X.....	93
17- IHC-stained BMB showing scattered DTCs arranged in singles, doubles & indian file that show positivity for CA15-3 McAb, 20X.....	94
18- Positive control for CA15-3 McAb, 20X.....	94
19- IHC-stained BMB showing occasional DTCs arranged in doubles or singles & show positivity for Cytokeratin (AE1/AE3) McAb, 20X.....	95
20- IHC –stained BMB showing DTCs arranged in singles, doubles and triples positive for Cytokeratin (AE1/AE3) McAb, 40X.....	95
21- IHC-stained BMB showing occasional DTCs arranged in singles, doubles & triples that show positivity for Mammaglobin McAb, 20X.....	96
22- IHC-stained BMB showing occasional DTCs arranged in singles & doubles that show positivity for Mammaglobin McAb, 40X.....	96
23- Positive control for Mammaglobin McAb, 20X.....	96

LIST OF ABBREVIATIONS

Abs	Antibodies
AJCC	American Joint Committee on Cancer
AML	Acute myeloid leukemia
ALN	Axillary lymph node
ASCO	American Society of Clinical Oncology
ASIS	Anterior superior iliac spine
BC(s)	Breast cancer(s)
BCCs	Breast cancer cells
BM	Bone marrow
BMA	Bone marrow aspiration
BMB	Bone marrow biopsy
BMM	Bone marrow micrometastases
CA15.3	Carcinoma antigen 15-3
CAP	College of American Pathologists
CEA	Carcino embryonic antigen
CGH	Comparative genomic hybridization
CIS	Carcinoma in situ
CK(s)	Cytokeratin(s)
CML	Chronic Myeloid Leukemia
CR-TM	Cancer related thrombotic microangiopathy
CTCs	Circulating tumor cells
DAB	Di-amino-Benzidine
DCIS	Ductal carcinoma in situ
DTCs	Disseminated tumor cells
ECD	Extracellular domain
EGFR	Epidermal growth factor receptor
ELISPOT	Enzyme linked immunospot
EMA	Epithelial membrane antigen
EPISPOT	Epithelial immunospot
ER	Estrogen receptor
FC	Flowcytometry

FDA	Food and Drug Administration
FISH	Fluorecent IN Situ Hybridization
FM	Fluorecent microscope
GVHD	Graft versus host disease
HCL	Hairy cell leukemia
HD	Hodgkin`s disease
HER-2/ECD	HER-2/extracellular domain
HRP	Horse raddish peroxidase
ICC	Immunocytochemistry
IDC	Invasive ductal carcinoma
IGF-1	Insulin like growth factor receptor -1
IHC	Immunohistochemistry
ILC	Invasive lobular carcinoma
IMF	Idiopathic myelofibrosis
IMS	Immunomagnetic selection
LCIS	Lobular carcinoma in situ
LEA	Leucoerythroblastic anemia
LN	Lymph nodes
MAHA	Microangiopathic hemolytic anemia
MAM	Mammaglobin
McAbs	Monoclonal antibodies
MEIA	Micro-particle enzyme immunoassay
MHC	Major Histocompatibility Complex
MM	Multiple myeloma
MRD	Minimal residual disease
MUC 1	Mucins
MUP	4-Methyl-umbelliferyl phosphate
NCDB	National Cancer Institute Data Base
NHL	Non Hodgkin`s lymphoma
NOS	Not otherwise specified
PB	Peripheral blood
PBS	Phosphate buffer saline
PC	Primary chemotherapy
PCR	Polymerase chain reaction
PIP	Prolactin inducible protein

PR	Progesterone receptor
PSIS	Posterior superior iliac spine
qRT-PCR	Quantitative RT-PCR
RS	Reed Sternberg cells
RT-PCR	Reverse transcription polymerase chain reaction
SD	Standard deviation
SLN	Sentinel lymph node
SPSS	Statistical Package for social science
TM	Thrombotic microangiopathy
TNM	Tumor Node Metastases
TTP	Thrombotic thrombocytopenic purpura
UICC	International Union against Cancer
US	United States
VWF	Von Willebrand factor

INTRODUCTION

Breast cancer is considered a systemic disease in which a hematogeneous tumor cell dissemination, essentially to bone marrow [the host organ for breast cancer metastases], may occur at very early stages of primary tumor development and form an occult isolated tumor cells, that subsequently lead to an overt metastases (Pantel et al, 1999). Disseminated tumor cells, the most precise term are also described by several synonyms as bone marrow micrometastases or minimal residual disease (Vincent-Salmon et al, 2008). Micrometastases are microscopic [smaller than 2 mm] deposits of malignant cells that are segregated spatially from the primary tumor and depend on neovascular [angiogenesis] formation to propagate (Kell et al, 2000).

The presence of bone marrow disseminated tumor cells at primary diagnosis of breast cancer is a strong independent predictive and prognostic factor for unfavorable clinical outcome (Molino et al, 1997 ; Braun et al, 1998 ; Mansi et al, 1999 ; Braun et al, 2000 ; Muller & Schilmok, 2000 ; Simmons et al, 2000 ; Solakoglu et al, 2002 ; Schleiermacher, et al, 2003 ; Braun et al, 2005 ; Muller & Pantel, 2005 ; Landys 2006 ; Bidard et al, 2007 ; Xenidis et al, 2007 ; Fehm et al, 2008).

Bone marrow biopsy has been suggested as independent prognostic tool to improve staging in patients with breast cancer. Ultrastaging of breast cancer patients may identify a substantial subgroup of lymph node -/bone marrow- patients who may not require adjuvant chemotherapy as well as lymph node-/bone marrow+ patients with a decreased survival who may need more aggressive therapies (Fortunato et al, 2006). The current challenge for pathologists is to improve and standardize early detection of disseminated tumor cells. Immunocytochemistry currently remains the gold standard for bone marrow disseminated tumor cells detection with a sensitivity ranging from 1 disseminated tumor cell in 10^5 to 1 in 10^6 leucocytes (Vincent-Salmon et al, 2008).

Several markers have been used to detect disseminated tumor cells in the bone marrow of breast cancer patients (Stathopoulo et al, 2002). To date Cytokeratins have become the most widely accepted protein marker for the detection of epithelial tumor cells in bone marrow (Braun et al, 2000).

Mammaglobin is a breast [cancer] specific marker (Lacroix 2006), that is almost expressed in breast epithelial cells. It is overexpressed in a subset of 70% - 80% of primary and metastatic breast cancer tissues and can be used for identification of breast cancer cells in bone marrow (Zehenter et al, 2004).

Serum CA15.3 tumor marker has a prognostic relevance in early stage breast cancer with an elevated level at the time of primary diagnosis could be a predictor of worse out come at both univariate and multivariate (Ebeling et al, 2002) analysis

Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with primary breast cancer at surgery will certainly play a role in the near future for risk stratification and monitoring of therapeutic efficacy in clinical management of patients with breast cancer (Vincent-Salmon et al, 2008).